SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)

SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)

No trades
See on Supercharts

0QN1 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

0QN1 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company